Application of circulating miRNA as a diagnostic marker for age-related macular degeneration

A diagnostic kit was developed by detecting circulating miRNA markers hsa-miR-195-5p, hsa-miR-27a-3p, or has-miR-29b-3p in plasma, solving the problem of early diagnosis of age-related macular degeneration and achieving highly efficient early diagnosis.

CN105861728BActive Publication Date: 2024-11-19SHANGHAI TENTH PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201610405838.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2016-06-12
Publication Date
2024-11-19
Estimated Expiration
2036-06-12

AI Technical Summary

Technical Problem

Current technologies lack effective early diagnostic biomarkers for detecting age-related macular degeneration (AMD), making it impossible to identify high-risk individuals for early intervention.

Method used

Diagnostic reagents or kits can be developed for early diagnosis by using circulating miRNA markers hsa-miR-195-5p, hsa-miR-27a-3p, or has-miR-29b-3p to detect the expression levels of these miRNAs in plasma.

Benefits of technology

The AUCs of miR-27a-3p, miR-29b-3p, and miR-195-5p were 79.1%, 72.7%, and 70.7%, respectively, demonstrating their high efficiency and feasibility as diagnostic biomarkers and improving the accuracy of early diagnosis of AMD.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN105861728B_ABST
    Figure CN105861728B_ABST
Patent Text Reader

Abstract

The present invention relates to the application of circulating miRNA as a diagnostic marker for age-related macular degeneration. The difference in miRNA expression between patients with neovascular AMD and cataract patients was detected by miRNA expression chip, 10 of all differentially expressed miRNAs were selected for verification, and then the sample was expanded, and the expression of specific miRNA was performed by fluorescent quantitative PCR method, and the content of differential miRNA in AMD patients and control group was compared to verify its feasibility as a diagnostic marker. ROC curve analysis showed that the AUCs of miR-27a-3p, miR-29b-3p and miR-195-5p were 79.1%, 72.7% and 70.7%, respectively. This shows that miR-27a-3p, miR-29b-3p and miR-195-5p can be used as diagnostic markers for age-related macular degeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of molecular biology and medical clinical diagnosis, and in particular to the application of circulating miRNA as a diagnostic marker for age-related macular degeneration. Background Art

[0002] Age-related macular degeneration (AMD) is one of the most important causes of irreversible blindness in people over 50 years old. According to a survey in the United States, the prevalence of AMD in people over 40 years old is 9%. Epidemiological surveys conducted in Handan and Beijing, China, showed that the prevalence of AMD in the elderly was 3.1% and 5.5%, respectively. Age, racial differences, genetics and smoking history are risk factors for the occurrence of AMD, and there are inconsistent reports on the relationship between other factors such as obesity and heart disease and the onset of AMD. Despite dietary and lifestyle interventions, as well as the use of antioxidant drugs, intravitreal drug injections, laser photocoagulation and photodynamic therapy, there is currently no effective cure for AMD.

[0003] The earliest pathological change of AMD is the appearance of drusen, which is the hallmark change of AMD, that is, the lesion deposition of polymorphic acellular debris between the retinal pigment epithelium (RPE) and Bruch's membrane. According to the size, drusen are divided into small (<63μm), medium (63-124μm), and large (>124μm); according to the edge morphology of drusen, they are also divided into hard and soft drusen. Damage to RPE cells and abnormal chronic inflammatory response can lead to large areas of retinal atrophy or abnormalities of neovascularization factors such as vascular endothelial growth factor (VEGF), and both can occur at the same time. In some patients, abnormalities of collagen or elastin in Bruch's membrane, outer retina and choroid are also pathological changes of AMD. The development of choroidal neovascularization is associated with increased vascular permeability and fragility, while CNV is closely related to subretinal hemorrhage, fluid exudation, lipid deposition, RPE and choroidal detachment. AMD is divided into dry AMD and wet AMD, and choroidal neovascularization is an important sign of wet AMD. It is currently believed that AMD is a complex process in which genetic factors and environmental factors work together, and inflammatory response, cell apoptosis, changes in cholesterol metabolism, angiogenesis and oxidative stress response interact with each other.

[0004] At present, the classification and staging of AMD are still based on the results of fundus examination: dry AMD and wet AMD are classified according to the presence or absence of exudation; early AMD and late AMD are classified according to the presence of drusen. However, once discovered, even for early AMD, there is currently no definite means of intervention to prevent the progression of the disease. Therefore, there is an urgent need to find effective, sensitive and specific biomarkers in clinical practice, that is, an objective indicator that precedes clinical manifestations, to separate high-risk groups and provide early intervention. However, the validation study of disease molecular markers is a complex process, which generally includes five stages: first, preclinical discovery and validation; second, clinical experimental validation; third, evaluation of its sensitivity and specificity in a complete clinical experiment; fourth, prospective evaluation of large and small sample analysis of typical diseases to determine its false positive rate; and finally, in terms of disease control, the contribution of molecular markers to the occurrence or alleviation of the disease is discovered. The acquisition of disease biomarkers usually takes a long process.

[0005] Micro ribonucleic acids (miRNA) are non-coding ribonucleic acids (RNA) with a length of 21-25 nucleotides. They regulate gene expression by binding to the 3' untranslated region (3' UTR) of target messenger ribonucleic acid (mRNA) to induce mRNA degradation or prevent its translation. Studies have shown that miRNAs play an important role in inflammatory response, oxidative stress response, angiogenesis, tumor growth, etc., and some miRNAs are important oncogenes or tumor suppressor genes. Serum miRNA-21 and miRNA-221, miRNA-376c and miRNA-744 can be used as biomarkers for liver cancer and gastric cancer, respectively. In tumors and cardiovascular diseases, miRNAs have attracted attention as new therapeutic targets. MiR-27a, a miRNA located at 19p13.13, plays an important role in tumor formation, cell proliferation, apoptosis and differentiation. It has been reported that miR-27a can regulate the sensitivity of brain cells to apoptosis by inhibiting apoptotic protease activating factor-1 (APAF-1), thereby affecting brain development. MiR-29b-3p and miR-195-5p are located on chromosomes 18 and 17, respectively. They play an important role in cell differentiation and tumor formation. They are also important factors in the diagnosis and prognosis of many diseases.

[0006] Chinese patent 2010101627286 provides a kit for detecting age-related macular degeneration, including optional reagents for detecting rs1061170 variation in exon 9 of CFH gene, rs1329428 variation in intron 15, rs800292 variation in exon 2 and / or rs3753394 variation in 5' non-coding region for AMD screening and diagnosis. By detecting whether there are variations in the above sites, the risk of age-related macular degeneration is detected, which has a high correlation with AMD. It can be used for early monitoring and detection of high-risk groups for AMD, early prevention and treatment, and reduction of visual impairment. Chinese patent 2007101628662 provides a kit for detecting age-related macular degeneration, which can be used for early monitoring and detection of high-risk groups for AMD, early prevention and treatment, and reduction of visual impairment. The HTRA1 gene 512G→A mutation and its related sites / genes are targeted, which have a high correlation with AMD, and the analysis of CHF gene mutations can be coordinated to improve the accuracy of detection. However, there is no report on the use of the circulating miRNA of the present invention as a diagnostic marker for neovascular age-related macular degeneration. Summary of the invention

[0007] The purpose of the present invention is to provide a marker for early diagnosis of age-related macular degeneration in view of the deficiencies in the prior art.

[0008] Another object of the present invention is to provide the use of the miRNA marker as described above.

[0009] To achieve the above object, the technical solution adopted by the present invention is:

[0010] A marker for early diagnosis of age-related macular degeneration, wherein the marker is a circulating miRNA marker selected from any one or more of the following miRNAs: hsa-miR-195-5p, hsa-miR-27a-3p or has-miR-29b-3p.

[0011] The sequence of hsa-miR-195-5p is uagcagcacagaaauauuggc, the sequence of hsa-miR-27a-3p is uucacaguggcuaaguuccgc, and the sequence of has-miR-29b-3p is uagcaccauuugaaaucaguguu. The nucleotide sequence of hsa-miR-195-5p is shown in SEQ ID NO.1; the nucleotide sequence of hsa-miR-27a-3p is shown in SEQ ID NO.2; and the nucleotide sequence of has-miR-29b-3p is shown in SEQ ID NO.3.

[0012] The age-related macular degeneration is dry age-related macular degeneration or wet age-related macular degeneration.

[0013] To achieve the above second purpose, the technical solution adopted by the present invention is:

[0014] The use of the miRNA markers as described above is used to prepare an early diagnostic reagent or kit for detecting age-related macular degeneration.

[0015] The miRNA marker is selected from one or more of the following miRNAs: hsa-miR-195-5p, hsa-miR-27a-3p or has-miR-29b-3p.

[0016] The test is a plasma test.

[0017] The sequence of hsa-miR-195-5p is uagcagcacagaaauauuggc, the sequence of hsa-miR-27a-3p is uucacaguggcuaaguuccgc, and the sequence of has-miR-29b-3p is uagcaccauuugaaaucaguguu. The nucleotide sequence of hsa-miR-195-5p is shown in SEQ ID NO.1; the nucleotide sequence of hsa-miR-27a-3p is shown in SEQ ID NO.2; and the nucleotide sequence of has-miR-29b-3p is shown in SEQ ID NO.3.

[0018] The diagnostic reagent or kit includes: a probe, a gene chip, or a PCR primer with detection specificity for one or more of hsa-miR-195-5p, hsa-miR-27a-3p, and has-miR-29b-3p. The sequences of the quantitative PCR primers for hsa-miR-195-5p are shown in SEQ ID NO.4-5; the sequences of the quantitative PCR primers for hsa-miR-27a-3p are shown in SEQ ID NO.6-7; and the sequences of the quantitative PCR primers for has-miR-29b-3p are shown in SEQ ID NO.8-9.

[0019] The age-related macular degeneration is dry age-related macular degeneration or wet age-related macular degeneration.

[0020] The advantages of the present invention are:

[0021] The present invention detects the difference in miRNA expression between patients with neovascular AMD and cataract patients through miRNA expression chips, selects 10 from all differentially expressed miRNAs for verification, then expands the sample, uses fluorescent quantitative PCR to perform specific miRNA expression, compares the content of differential miRNA in AMD patients and the control group, and verifies its feasibility as a diagnostic marker. ROC curve analysis shows that the AUCs of miR-27a-3p, miR-29b-3p and miR-195-5p are 79.1%, 72.7% and 70.7%, respectively. This indicates that miR-27a-3p, miR-29b-3p and miR-195-5p can be used as diagnostic markers for age-related macular degeneration. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Attached Figure 1 Fundus photos, OCT and FFA results of CNV AMD.

[0023] Attached Figure 2 Gel electrophoresis was used to test the quality of RNA extraction from samples.

[0024] Attached Figure 3 Cluster analysis of related miRNA expression.

[0025] Attached Figure 4 GO analysis results for the chip results.

[0026] Attached Figure 5 It is the main signaling pathway related to the pathogenesis of AMD.

[0027] Attached Figure 6 Figure 2 is the relationship diagram of miRNA target genes.

[0028] Attached Figure 7 It is the target gene of miR-27a-3p. miR-27a-3p is mainly related to cell differentiation, apoptosis, proliferation, migration and invasion. Important target genes of miR-27a-3p include Apaf-1, Hsp110, Hsp90, sFRP and other genes, which play a role in the development of many diseases.

[0029] Attached Figure 8 It is a target gene of miR-29a-3p. miR-29b-3p is mainly related to apoptosis, proliferation, angiogenesis and fibrosis. Important target genes of miR29b-3p include Smad3, MCL-1, VEGFA, ELN, FBN1, COL1A1, COL1A2, COL3A1 and other genes, which play a role in the development of many diseases. VEGFA is significantly associated with angiogenesis, while COL1A1 and COL1A2 are closely related to fibrosis and extracellular matrix formation.

[0030] Attached Fig. 9 It is the target gene of miR-195-3p. miR-195-3p is closely related to the cell cycle, tumor growth and invasion. Important target genes of miR-195-3p include Bcl-w, pRb636, BDNF and other genes, which play a role in the development of many diseases.

[0031] Attached Fig.10 Fundus photography, OCT and FFA results of dry AMD.

[0032] Attached Fig.11 The differences of miRNAs between AMD group and control group.

[0033] Attached Fig.12 The differentially expressed miRNAs in different types of AMD.

[0034] Attached Fig.13 The ROC curves of miR-27a-3p, miR-29b-3p and miR-195-5p were, and the areas under the ROC curves (AUC) were 79.1% (95% CI = 71.4% -86.8%), 72.7% (95% CI = 64.1% -80.0%) and 70.7% (95% CI = 61.7% -79.7%), respectively. DETAILED DESCRIPTION

[0035] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0036] Example 1 Analysis of circulating miRNA expression profiles in CNV AMD patients using microarray

[0037] 1. Materials and Methods

[0038] 1. Research subjects

[0039] All the research subjects were patients who visited the Department of Ophthalmology of the Tenth People's Hospital Affiliated to Tongji University from June 2012 to July 2012, and all selected patients signed informed consent.

[0040] 1.1 Experimental group (CNV AMD patients)

[0041] 1.1.1 Selection criteria

[0042] Patients with CNV-related age-related macular degeneration were diagnosed by fundus photography (FP), optical coherence tomography (OCT), fluorescein fundus angiography (FFA) examinations combined with visual acuity changes.

[0043] Diagnostic criteria for CNV AMD:

[0044] (1) Corrected visual acuity < 0.5, with possible visual distortion and fixation-related shadows in front of the eyes.

[0045] (2) Fundus photography: There are fused drusen with unclear boundaries and subretinal hemorrhage in the macular area.

[0046] (3) OCT: It manifests as a red reflective band of the retinal pigment epithelium / choroidal capillaries layer with localized thickening. CNV is a larger area of ​​irregular thickening accompanied by deformation of the retinal pigment epithelium / choroidal capillaries layer with clear boundaries.

[0047] (4) Fundus fluorescein angiography (FFA): When fluorescence is visible, it indicates atrophy of the retinal pigment epithelium. The pigmented areas may block the fluorescence and in the later stage there may be leakage of fluorescein.

[0048] Figure 1 Fundus photography (A), OCT (B) and FFA (C) results of CNV AMD.

[0049] 1.1.2 Exclusion criteria

[0050] (1) Inflammation of the anterior segment of the eye, such as active conjunctivitis, keratitis, uveitis, etc.;

[0051] (2) Suffering from fundus diseases other than AMD, such as macular hole, macular edema, high myopia, retinal vascular occlusion, central serous chorioretinopathy, and other fundus diseases;

[0052] (3) Systemic diseases: organic diseases such as diabetes, malignant tumors, Alzheimer's disease, stroke, and autoimmune system diseases;

[0053] (4) Other reasons prevent the completion of relevant inspections and studies.

[0054] 1.2 Control group

[0055] 1.2.1 Inclusion criteria

[0056] (1) Patients who come to the hospital for treatment after cataract extraction.

[0057] (2) Age and gender were matched with those of the experimental group.

[0058] 1.2.2 Exclusion criteria

[0059] (1) Inflammation of the anterior segment of the eye, such as active conjunctivitis, keratitis, uveitis, etc.;

[0060] (2) Suffering from fundus diseases other than AMD, such as macular hole, macular edema, high myopia, retinal vascular occlusion, central serous chorioretinopathy, and other fundus diseases;

[0061] (3) Systemic diseases: organic diseases such as diabetes, malignant tumors, Alzheimer's disease, stroke, and autoimmune system diseases;

[0062] (4) Other reasons prevent the completion of relevant inspections and studies.

[0063] 1.3 General information of included subjects

[0064] There were 6 patients in the experimental group and 6 patients in the control group, and there were statistically significant differences in age and gender (P>0.05). See the table below for details.

[0065] Experimental Group Control group P N 6 6 Eye (human) 6 6 men and women 4 / 2 4 / 2 0.727 age 68.5±7.8 65.7±6.9 0.525

[0066] 2. Main experimental equipment and reagents

[0067]

[0068]

[0069] 3. Research Methods

[0070] 3.1 Specimen collection, storage and transportation

[0071] 2 ml of whole blood was drawn from the subjects and stored in 5 ml EDTA anticoagulant vacuum tubes. The samples were packaged in 400-500 ul / tubes. For short-term storage, they were placed in a -80°C refrigerator. Sufficient dry ice was used during transportation to ensure that the temperature was always low.

[0072] 3.2 RNA isolation and identification

[0073] RNA was extracted from whole blood using TRIZOL. The specific steps are as follows:

[0074] 1. Add 0.2 ml of whole blood to 0.75 ml of TRI Reagent BD. Add 20 ul of 5N acetic acid to every 0.2 ml of whole blood or plasma and mix thoroughly.

[0075] 2. Leave the lysate at room temperature for 5 minutes to allow the nucleoprotein complex to fully dissociate. Next, add 0.1 ml of bromochloropropane or 0.2 ml of chloroform to every 0.75 ml of lysate, cover tightly, and shake vigorously for 15 seconds. Leave the mixture at room temperature for 2 to 5 minutes, and centrifuge at 12,000g, 4°C for 15 minutes. After centrifugation, the mixture is divided into a lower brown phenol-chloroform phase, an intermediate phase, and an upper colorless aqueous phase. RNA is retained in the aqueous phase, and DNA and protein are in the intermediate phase and organic phase, respectively.

[0076] 3. RNA precipitation: Transfer the aqueous phase to a new centrifuge tube, and store the interphase and organic phase at 4°C for subsequent experiments. Add isopropanol to the aqueous phase and mix well to precipitate RNA. Add 0.5 ml of isopropanol to each 0.75 ml of the aqueous phase separated by TRI Reagent BD. Leave at room temperature for 5-10 minutes, and centrifuge at 12,000g, 4-25°C for 8 minutes. The RNA precipitate appears as a gelatinous or white precipitate at the bottom of the tube.

[0077] 4. Wash RNA: Aspirate the supernatant, add 75% ethanol, and vortex to resuspend the RNA precipitate. Wash the RNA extracted with 1 ml 75% ethanol for every 0.75 ml TRIreagent BD reagent. If the previous separation step was performed in a large centrifuge tube (> 2 ml), transfer the RNA-ethanol suspension to a small centrifuge tube. When transferring, use a 1 ml pipette tip with a caliber minus 2 to 3 mm and centrifuge at 7,500g for 5 minutes at 4 to 25°C. If the RNA precipitates on the wall of the tube or cannot adhere to the wall, use 12,000g centrifugation.

[0078] 5. Dissolve RNA: Aspirate the ethanol and let the RNA precipitate air dry for 5 minutes. Be careful not to dry the RNA completely, otherwise it will reduce the solubility of the RNA. Also avoid using a vacuum device to centrifuge and dry the RNA. Dissolve the RNA with FORMAzol (cat. no. FO121), water, or a 0.5% SDS solution prepared by blowing and mixing with a pipette tip, and incubate at 55-60°C for 10-15 minutes. The water or SDS solution used to dissolve the RNA must first be treated with DEPC.

[0079] 6. RNA quality control: Use EB to stain the RNA separated by agarose gel electrophoresis, or use methylene blue to stain the RNA transferred to the hybridization membrane. Two main bands can be seen, which are 2kb and 5kb rRNA, and there is also a small molecular weight RNA of 0.1-0.3kb. After extracting total RNA, the quality detection standard: A260 / A230 value is greater than 2.0, and A260 / A280 value is between 1.8-2.0, indicating good RNA quality.

[0080] 3.3 miRNA expression profile study

[0081] 3.3.1 Expression profile operation and data analysis

[0082] By miRCURY TM Hy3 TM / Hy5 TM The labeling kit prepared the target RNA from 12 samples of whole blood that had passed the quality test and compared it with the miRCURY TM The chip hybridization was performed using a locked nucleotide chip (v.18.0). After the chip was washed and stained, it was scanned by an AxonGenePix 4000B microarray scanner, and the miRNA chip analysis system (GenePix Pro 6.0 software, Axon) was used to screen out the miRNAs that were differentially expressed in the two groups of cycles. We selected non-control probes with a correction value of ≥30 on each chip in a batch of experiments for standardization, and used the median of this part of the probes as the normalization factor to normalize the points of the entire chip, that is, each miRNA correction value / median = Normalized Data (standard value).

[0083] We use the standard values ​​of miRNAs in Differentially Expressed miRNAs (Pass Volcano Plot) for clustering analysis (hierarchical clustering), and samples or miRNAs with close relationships will be clustered together. The correlation coefficient R (Correlation coefficient R-value) indicates the level of correlation between repeated samples or the difference between samples in different groups. The better the repeatability, the larger the R value, and the greater the difference, the smaller the R value. Scatter plot graphically shows the difference in miRNA expression between two samples. The greater the difference between the two samples, the farther the scatter plot is from the straight line X=Y, and the greater the degree of dispersion.

[0084] 3.3.2 Bioinformatics analysis

[0085] (1) Forecasting data sources and strategies

[0086] The prediction information of three databases, mirbase, miranda and targetscan, is used. The final prediction result is the overlapping part, usually the overlapping part of the three data prediction results.

[0087] (2) Database information

[0088] Microcosm:http: / / www.ebi.ac.uk / enright-srv / microcosm / htdocs / targets / v5 /

[0089] Miranda:http: / / www.microrna.org / microrna / home.do

[0090] Targetscan: the targetscan version 6.2(http: / / www.targetscan.org / vert_60 / )

[0091] The target gene information of hg19, mm9, and RN34 comes from these three

[0092] 4. Statistical analysis

[0093] According to the experimental design, two independent sample t tests, one-way ANOVA, and chi-square analysis were used for statistical analysis. LSD and SNK methods were used to compare the differences between groups. SPSS19.0 software was used for the above statistical analysis. P<0.05 was considered statistically significant. Each group of experiments was repeated three times, and the average value was taken for calculation.

[0094] 5. Results

[0095] 5.1 RNA extraction quality detection and identification

[0096] A total of 12 samples were used for circulating miRNA expression profiling analysis. All samples were extracted by Trizol, and the integrity and quality of RNA were tested by detecting the absorbance of RNA solution and gel electrophoresis of RNA. From the results in Table 1, it can be found that the OD260 / A280 of all samples was between 1.82 and 1.91, and the OD260 / 230 was more than 1.8, indicating that the RNA extraction quality was good and could be used for further experiments. Various RNA extraction concentrations were 200ng / μl, which was also suitable for further experiments. Gel electrophoresis ( Figure 2 ) showed that the 8S and 18S bands were bright, clear, and sharp, with clear edges, indicating that the RNA quality was good.

[0097] Table 1 Absorbance detection of sample RNA extraction quality

[0098]

[0099] 5.2 Analysis of differentially expressed miRNAs

[0100] Figure 3The cluster analysis results provided by the chip results are shown. After processing the background signal and balancing the differences between chips, the test results show that a total of 216 differentially expressed miRNAs were detected from circulating miRNAs (of which 111 were increased in expression and 105 were decreased in expression).

[0101] Because the number of differentially expressed miRNAs was large, we selected candidate miRNAs with a P value < 0.05 and a standardized signal intensity difference of ≥ 2-fold for further study. A total of 35 miRNAs were detected, of which 15 were upregulated (fold > 2.0) and 20 were downregulated (fold < 0.5), as shown in Table 2.

[0102] Table 2 Microarray analysis showed up-regulated and down-regulated miRNAs

[0103]

[0104] Bioinformatics analysis

[0105] 5.3.1 GO classification

[0106] GO analysis results showed that in the GO classification of miRNAs in AMD patients, the top three were cellular process (656), biological regulation (498), and the genes related to metabolic process (490) were significantly changed ( Figure 4 ).

[0107] 5.3.2 Distribution of target genes related to miRNAs in signaling pathways

[0108] In order to understand the distribution of target genes related to miRNAs in signal pathways, we conducted informatics analysis of signal pathways. The results showed that the top three signal pathways involved in the progression of AMD were cell cycle-related pathways, followed by extracellular matrix receptor interactions and changes in tumor signal pathways. Figure 5 ). It can be seen that cell cycle changes play an important role in the occurrence and progression of AMD, and the specific content needs to be further studied in this study.

[0109] 5.3.3 Target gene prediction

[0110] Considering that there are many possible target genes of candidate miRNAs, we plotted the target genes predicted by miRNAs and their interrelationships and obtained the 10 most important nodes, whose corresponding miRNAs are: miR-152, miR-27a-3p, miR-28-5p, miR-195-5p, miR-559, miR-328, miR-25-3p, miR-29b-3p, has-let-7c, and miR-584-5p. Figure 6 A relationship diagram of miRNA target genes is shown, and each miRNA is labeled in the figure. Figure 7-9 The target genes of miR-27a-3p, miR-29b-3p and miR-195-5p are shown.

[0111] Example 2 Validation study of differentially circulating miRNAs

[0112] 1. Materials and Methods

[0113] 1. Research Methods

[0114] All the research subjects were patients who visited the Department of Ophthalmology of the Tenth People's Hospital Affiliated to Tongji University from June 2012 to September 2012, and all of them signed informed consent.

[0115] 1.1 Clinical sample selection

[0116] 1.1.1 Experimental Group

[0117] Inclusion criteria: Patients diagnosed with CNV age-related macular degeneration by fundus photography (FP), optical coherence tomography (OCT), fluorescein fundus angiography (FFA) examination combined with visual acuity changes. The inclusion criteria for neovascular AMD are the same as those in Example 1, and the inclusion criteria for dry AMD are as follows:

[0118] (1) There was no significant effect on visual acuity, and the central visual acuity of all patients was >0.4.

[0119] (2) Fundus manifestations: pigment disorder in the macular area, unclear foveal reflection, and scattered drusen can be seen.

[0120] (3) OCT: small hillock-like lesions with moderate to strong reflectivity may be seen, with or without abnormalities in the RPE reflective bands and the retinal inner and outer segment reflective bands.

[0121] (4) Fundus fluorescein angiography: When fluorescence is visible, it indicates atrophy of the retinal pigment epithelium. The pigmented areas may obstruct fluorescence and have lace-like or reticular neovascularization.

[0122] Fig.10 Fundus photography (A), OCT (B) and FFA (C) results of dry AMD.

[0123] The exclusion criteria are the same as in Example 1.

[0124] 1.1.2 The inclusion and exclusion criteria for the control group were the same as those in Example 1.

[0125] 1.2 General information of the subjects included

[0126] In the control study with expanded samples, a total of 125 participants (65 experimental group and 60 control group samples, including chip expression profile samples) were included in the study. There was no statistical difference in age and gender between the two groups (P>0.05). In the experimental group, 42 people had dry AMD and 23 people had wet AMD. The control group was mainly composed of patients with senile cataract.

[0127] Experimental Group Control group P N 65 60 Eye (human) 72(65) 60 men and women 38 / 27 36 / 24 0.503 age 56.5±9.8 53.7±8.6 0.09

[0128] 2. Main experimental equipment and reagents

[0129]

[0130]

[0131] 3. Research Methods

[0132] 3.1 Specimen collection, storage and transportation

[0133] 2 ml of whole blood was drawn from the subjects, stored in 5 ml EDTA anticoagulant vacuum tubes, mixed to prevent blood coagulation. The samples were divided into 400-500 ul / tube and placed in a -80℃ refrigerator.

[0134] 3.2 RNA isolation and identification

[0135] The miRcute miRNA extraction and isolation kit (Tiangen Co., Ltd.) was used for RNA extraction to expand the sample to verify the chip results. The operation is as follows:

[0136] (1) Sample processing: Add an equal volume of lysis buffer MZ to every 200 μl of whole blood and mix by oscillating on an oscillator for 30 seconds.

[0137] (2) Leave at room temperature for 5 min to allow the nucleic acid-protein complex to completely separate.

[0138] (3) Centrifuge at 12,000 rpm (~13,400 × g) for 10 min at room temperature, remove the supernatant and transfer it to a new RNase-free centrifuge tube.

[0139] (4) Add 200 μl of chloroform, cover the tube, shake vigorously for 15 seconds, and leave at room temperature for 5 minutes.

[0140] (5) Centrifuge at room temperature at 12,000 rpm (~13,400 × g) for 15 min. The sample will separate into three layers: a yellow organic phase, an intermediate layer, and a colorless aqueous phase. RNA is mainly in the aqueous phase. Transfer the aqueous phase to a new tube and proceed to the next step.

[0141] (6) Measure the volume of the transfer solution, slowly add 1 / 3 volume of anhydrous ethanol to the transfer solution, and mix well. Transfer the resulting solution and precipitate to the adsorption column miRspin, place at room temperature for 2 min, and centrifuge at 12,000 rpm (~13,400 × g) for 30 s at room temperature. After centrifugation, discard the adsorption column miRspin and retain the effluent.

[0142] (7) Measure the volume of the effluent, slowly add 2 / 3 of the volume of anhydrous ethanol, and mix well (precipitate may appear at this time). Transfer the resulting solution and precipitate into the adsorption column miRelute, let it stand at room temperature for 2 minutes, and centrifuge it at 12,000 rpm (~13,400×g) for 30 seconds at room temperature. After centrifugation, discard the effluent and retain the adsorption column miRelute.

[0143] (8) Add 500 μl of deproteinized MRD solution to the adsorption column miRelute, let stand at room temperature for 2 min, centrifuge at 12,000 rpm (~13,400 × g) at room temperature for 30 s, and discard the waste liquid.

[0144] (9) Add 600 μl of RW to the miRelute column, let stand at room temperature for 2 min, centrifuge at 12,000 rpm (~13,400 × g) for 30 s, and discard the waste liquid. Repeat once.

[0145] (10) Place the miRelute adsorption column in a 2 ml collection tube and centrifuge at 12,000 rpm (~13,400 × g) for 1 min at room temperature to remove the residual liquid. The purpose of this step is to remove the residual rinse liquid in the adsorption column. After centrifugation, place the miRelute adsorption column at room temperature for a while, or place it on a clean bench for ventilation for a while to fully dry. If there is any rinse liquid left, it may affect subsequent experimental operations such as RT.

[0146] (11) Transfer the miRelute adsorption column to a new 1.5 ml centrifuge tube, add 15–30 μl RNase-free ddH2O, incubate at room temperature for 2 min, and centrifuge at 12,000 rpm (~13,400 × g) for 2 min.

[0147] 3.3 Quality Inspection

[0148] Quality testing standards after total RNA extraction: A260 / A230 value greater than 2.0, A260 / A280 value between 1.8-2.0 indicates good RNA quality.

[0149] 4. Statistical analysis

[0150] According to the experimental design, two independent sample t tests, one-way ANOVA, and chi-square analysis were used for statistical analysis. LSD and SNK methods were used to compare the differences between groups. SPSS19.0 software was used for the above statistical analysis. The data in the figure are mean ± standard deviation (mean ± SD). ROC (Receiver Operating Characteristic) was used for specificity and sensitivity analysis. P < 0.05 was considered statistically significant. Each group of experiments was repeated three times, and the average value was taken for calculation.

[0151] 5. Results

[0152] 5.1 Differential expression of circulating miRNAs in AMD patients and controls

[0153] A total of 65 AMD patients (42 with dry AMD and 23 with wet AMD) and 60 controls were selected. Among all the differentially expressed miRNAs screened by miRNA expression microarray, we detected a total of 10 screened miRNAs (8 of which were upregulated: miR-152, miR-27a-3p, miR-28-5p, miR-195-5p, miR-559, miR-25-3p, miR-29b-3p, has-let-7c; 2 were downregulated: miR-328, miR-584-5p). Through real-time fluorescence quantitative PCR reaction (hsa-miR-195-5p: F cgcagtagcagcacaga, R tccagttttttttttttttttgcca, hsa-miR-27a-3p: Fcagttcacagtggctaagttc, R cagttttttttttttttttgcggaa, has-miR-29b-3p: Fcagtagcaccatttgaaatcagt, R ggtccagttttttttttttttttaacact), we found that compared with the control group, the expression of miR-27a-3p, miR-29b-3p and miR-195-5p increased significantly, with the increase folds of 2.76±1.78, 3.04±1.97 and 4.13±4.00, respectively. There was no significant difference in the changes of other miRNAs ( Fig.11 ).

[0154] 5.2 Differential expression of three specific miRNAs in different types of AMD

[0155] By analyzing the expression of the three differentially expressed miRNAs (miR-27a-3p, miR-29b-3p and miR-195-5p) in the whole blood of patients with different types of AMD, we found that the expression of the three miRNAs in dry AMD and wet AMD was significantly higher than that in the control group, which was consistent with the previous results. In addition, we found that for miR-27a, the content of wet AMD patients was lower than that of dry AMD patients (21.2±7.9vs 32.0±8.8, P=0.009), while there was no significant difference in miR-29b-3p and miR-195-5p among different types of AMD (P>0.05)( Fig.12 ).

[0156] 5.3 Analysis of the efficacy of three specific miRNAs as molecular markers for AMD

[0157] We further analyzed the possibility of the three differentially expressed miRNAs as miRNA diagnostic markers through ROC curve analysis. After ROC curve analysis, we found that all three miRNAs can be used as diagnostic markers for AMD. The results showed that miR-27a-3p( Fig.13 .A), miR-29b-3p( Fig.13 .B) and miR-195-5p( Fig.13 .C) The areas under the ROC curve (AUC) were 79.1% (95% CI = 71.4%-86.8%), 72.7% (95% CI = 64.1%-80.0%) and 70.7% (95% CI = 61.7%-79.7%), respectively. When miR-27a-3p ≥ 11.2, the sensitivity was 83.7% and the specificity was 67.3%. When miR-29b-3p ≥ 9.18, the sensitivity was 62.1% and the specificity was 75.3%. When miR-195-5p ≥ 8.32, the sensitivity was 75.0% and the specificity was 53.9%.

[0158] 6. Discussion

[0159] In the study of miRNA expression profile chip, the difference of circulating miRNAs between patients with AMD and the control group was studied. It was found that 35 miRNAs (15 up-regulated and 20 down-regulated) were detected with the difference change amplitude ≥2 times as the standard. This suggests that the content of circulating miRNAs in AMD patients has changed to a certain extent during the development. The 10 differentially expressed miRNAs (miR-152, miR-27a-3p, miR-28-5p, miR-195-5p, miR-559, miR-25-3p, miR-29b-3p, has-let-7c, miR-328 and miR-584-5p) confirmed by the miRNA chip were selected for further verification. The results were consistent with the chip results, of which 8 miRNAs were up-regulated and 2 miRNAs were down-regulated, which also proved the credibility of the chip detection results. Among the 10 miRNAs, only 3 miRNAs showed differences in changes, with miR-27a-3p, miR-29b-3p and miR-195-5p increasing by 2.76, 3.04 and 4.13 times, respectively. Between the dry AMD and wet AMD groups, only the miR-27a-3p content was significantly different, and the circulating miR-27a-3p content in wet AMD patients was higher than that in dry AMD patients, suggesting the potential of further research on miR-27a-3p as a marker for AMD progression. The areas under the ROC curves for the three miRNAs were all greater than 50%, indicating that these three miRNAs can be used as diagnostic markers for AMD.

[0160] In the present invention, miR-27a-3p has the best sensitivity, which is 83.7%, and miR-29b-3p has the best specificity, which is 75.3%. The sum of specificity and sensitivity is the highest for miR-27a-3p, suggesting that the combined use of different miRNAs for the diagnosis of AMD can improve the sensitivity and specificity of diagnosis.

[0161] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. Use of a PCR primer pair for specifically detecting the circulating miRNA marker hsa-miR-27a-3p in the preparation of a diagnostic reagent for distinguishing dry age-related macular degeneration from wet age-related macular degeneration, characterized in that: The nucleotide sequence of the circulating miRNA marker hsa-miR-27a-3p is shown in SEQ ID NO: 2; the detection is a plasma detection; The sequences of the PCR primer pairs are shown in SEQ ID NOs: 6-7.